Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 548 across all filing types
Latest filing 2021-09-15 Regulatory Filings
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (BIO101) in COVID-19
Regulatory Filings Classification · 95% confidence The document is a press release titled "Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (BIO101) in COVID-19". It details the results of an interim analysis for a clinical trial and announces the continuation of the study. This type of announcement, which communicates key operational and clinical trial updates to investors and the public, is typically classified as an Earnings Release (ER) if it were tied to financial results, or more generally as a Regulatory Filing (RNS) if it's a broad operational update not covered by other specific categories. Since it is not a full financial report (10-K, IR), a management discussion (MDA), or a specific regulatory form, and it is an announcement of a significant operational event (clinical trial update), it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory/operational announcements not explicitly defined elsewhere. It is not a Report Publication Announcement (RPA) because it is the primary announcement of the results, not just an announcement that a report is available.
2021-09-15 English
Biophytis annonce les résultats de la deuxième analyse intermédiaire du DMC dans la « promising zone1 », permettant la poursuite de l’étude COVA de phase 2-3 de Sarconeos (BIO101) dans la COVID-19
Earnings Release Classification · 92% confidence The document is a press release from Biophytis dated September 15, 2021, announcing the results of the second interim analysis (IA2) of their Phase 2-3 COVA study for Sarconeos (BIO101) in COVID-19 patients. It details the recommendation from the independent Data Monitoring Committee (DMC) to continue the trial without protocol modification because the efficacy fell into the 'promising zone'. This type of announcement, which communicates key clinical trial progress, safety updates, and next steps (like expected results timeline and recruitment acceleration), is characteristic of an Earnings Release (ER) or a general press release related to operational/clinical progress. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy (DEF 14A), the most appropriate classification for a timely announcement of significant operational/clinical news is 'Earnings Release' (ER), as these often include operational highlights alongside financial results, or sometimes serve as the primary vehicle for such news when quarterly results are not the focus. Given the focus is purely on clinical trial progress and not financial performance highlights, it is a significant operational update. In the absence of a specific 'Clinical Trial Update' code, ER is often used for major operational announcements, or it could fall under RNS. However, ER is typically used for the initial release of period results/updates. Since this is a major clinical milestone announcement, ER is a strong candidate, but RNS (Regulatory Filings/General Announcement) is the safest fallback for non-standard operational news. Given the structure and content (announcing a key milestone/result), it functions similarly to an Earnings Release announcing operational results. I will classify it as ER based on the nature of reporting a key 'result' (DMC recommendation) and the length/format suggesting a primary announcement rather than a simple regulatory notice (RNS). Q3 2021
2021-09-15 French
Biophytis to attend key upcoming investor events and industry conferences
Report Publication Announcement Classification · 99% confidence The document is a press release announcing that the company's management will participate in several upcoming investor events and industry conferences between September and December 2021. It details the company's business, pipeline (Sarconeos/BIO101), and includes standard forward-looking statements and contact information. This type of announcement, which informs investors about management's schedule for meetings and presentations at external industry gatherings, does not fit the definitions for formal financial reports (10-K, IR, ER, AR) or specific corporate actions (DIV, SHA, CAP). It is a general communication to the investment community regarding outreach activities. Since it is not a transcript (CT), a proxy statement (PSI), or a director dealing report (DIRS), the most appropriate classification is a general Regulatory Filing (RNS), as it is a formal announcement made to the public/regulators about company activities, even if the content is promotional/informational regarding future events.
2021-09-14 English
Biophytis participera à plusieurs événements investisseurs et conférences clés du secteur
Investor Presentation Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and its primary content announces that Biophytis executives will participate in several key investor events and conferences between September and December 2021. This is an announcement about future corporate activities aimed at investors, rather than a full financial report (like 10-K or IR) or a specific regulatory filing like a Director's Dealing or Dividend Notice. Since the document is short and serves to inform stakeholders about upcoming engagement opportunities, it best fits the category for Investor Presentations or related communications. However, given the specific options, this announcement about attending investor events is most closely related to Investor Presentation (IP) or potentially a general Regulatory Filing (RNS) if it doesn't fit the specific presentation format. Since it is an announcement detailing future investor meetings, it is a form of investor relations communication. Given the options, 'Investor Presentation' (IP) is often used broadly for investor-facing communications, but 'Report Publication Announcement' (RPA) is for announcing reports. This is an announcement of *participation* in events. Since there is no specific category for 'Investor Event Schedule Announcement', and it is not a presentation itself, the closest fit among the provided options that covers investor-focused communications that aren't formal reports is often the general 'Regulatory Filings' (RNS) or sometimes 'Investor Presentation' (IP) if the context implies it's part of a broader investor outreach package. Given the nature of announcing participation in investor conferences, it is a form of investor relations communication. If we strictly follow the definitions, it is not a presentation (IP), nor is it announcing the publication of a formal report (RPA). It is a general corporate update. I will classify it as RNS as the fallback for general corporate announcements that don't fit the specific financial report types, although it strongly relates to investor relations activities.
2021-09-14 French
Biophytis leadership is reinforced with new Chief Medical Officer appointment
Board/Management Information Classification · 99% confidence The document is explicitly titled "Press release" and announces a significant change in senior personnel: the appointment of a new Chief Medical Officer (CMO). This directly aligns with the definition of Board/Management Information, which covers announcements of changes in senior management. The content focuses entirely on the appointment, the background of the new executive, and quotes from the CEO and the new CMO. This is not a financial report (10-K, IR, ER), a regulatory filing about transactions (DIRS, POS), or a general regulatory announcement (RNS).
2021-09-09 English
Biophytis renforce son équipe de direction avec la nomination d’un nouveau Directeur Médical
Board/Management Information Classification · 99% confidence The document is titled with a headline announcing a management change ("Biophytis renforce son équipe de direction avec la nomination d'un nouveau Directeur Médical") and details the appointment of Rob van Maanen as Chief Medical Officer. The text structure, including quotes from the CEO and the new appointee, is characteristic of a press release announcing executive changes. This directly aligns with the definition for Board/Management Information (MANG). It is not an Earnings Release (ER) as it focuses on personnel, nor is it a full Annual Report (10-K) or Interim Report (IR).
2021-09-09 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.